SI3221347T1 - Mutiran imunoglobulin-vezavni polipeptidi - Google Patents

Mutiran imunoglobulin-vezavni polipeptidi

Info

Publication number
SI3221347T1
SI3221347T1 SI201531353T SI201531353T SI3221347T1 SI 3221347 T1 SI3221347 T1 SI 3221347T1 SI 201531353 T SI201531353 T SI 201531353T SI 201531353 T SI201531353 T SI 201531353T SI 3221347 T1 SI3221347 T1 SI 3221347T1
Authority
SI
Slovenia
Prior art keywords
binding polypeptides
mutated immunoglobulin
mutated
immunoglobulin
polypeptides
Prior art date
Application number
SI201531353T
Other languages
English (en)
Inventor
Gustav Rodrigo
Tomas Bjorkman
Mats Ander
Original Assignee
Cytiva Bioprocess R&D Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1510261.9A external-priority patent/GB201510261D0/en
Priority claimed from GBGB1510263.5A external-priority patent/GB201510263D0/en
Application filed by Cytiva Bioprocess R&D Ab filed Critical Cytiva Bioprocess R&D Ab
Publication of SI3221347T1 publication Critical patent/SI3221347T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
SI201531353T 2014-11-17 2015-11-16 Mutiran imunoglobulin-vezavni polipeptidi SI3221347T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1451376 2014-11-17
GBGB1510261.9A GB201510261D0 (en) 2015-06-12 2015-06-12 Mutated immunoglobulin-binding polypeptides
GBGB1510263.5A GB201510263D0 (en) 2015-06-12 2015-06-12 Mutated immunoglobulin-binding polypeptides
PCT/EP2015/076639 WO2016079033A1 (en) 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides
EP15797940.2A EP3221347B1 (en) 2014-11-17 2015-11-16 Mutated immunoglobulin-binding polypeptides

Publications (1)

Publication Number Publication Date
SI3221347T1 true SI3221347T1 (sl) 2020-11-30

Family

ID=54695687

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531353T SI3221347T1 (sl) 2014-11-17 2015-11-16 Mutiran imunoglobulin-vezavni polipeptidi

Country Status (14)

Country Link
US (5) US11566082B2 (sl)
EP (4) EP3757123A1 (sl)
JP (5) JP6770727B2 (sl)
KR (2) KR102552335B1 (sl)
CN (2) CN107001432B (sl)
AU (2) AU2015348641B2 (sl)
BR (1) BR112017008106A2 (sl)
DE (1) DE112015005181T5 (sl)
DK (1) DK3221347T3 (sl)
ES (1) ES2817900T3 (sl)
RU (2) RU2701695C2 (sl)
SG (2) SG11201702796WA (sl)
SI (1) SI3221347T1 (sl)
WO (2) WO2016079033A1 (sl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
DK3233892T3 (da) 2014-12-17 2024-04-08 Cytiva Bioprocess R & D Ab Modificerede kappa-letkæde-bindende polypeptider
JP6891114B2 (ja) * 2015-07-22 2021-06-18 株式会社カネカ 酸性ｐＨ領域での抗体結合能が低下した抗体結合性タンパク質
GB201515339D0 (en) 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
WO2017191252A1 (en) 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
WO2017194592A1 (en) * 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455242B1 (en) * 2016-05-11 2021-06-23 Cytiva BioProcess R&D AB Separation method
JP7031934B2 (ja) * 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
CN109071612B (zh) * 2016-05-11 2022-10-25 思拓凡生物工艺研发有限公司 突变的免疫球蛋白结合多肽
WO2018029158A1 (en) * 2016-08-11 2018-02-15 Repligen Corporation Alkaline stable fc—binding proteins for affinity chromatography
GB201703116D0 (en) 2017-02-27 2017-04-12 Ge Healthcare Bioprocess R&D Ab A seperation matrix and a method of seperating antibodies
WO2018162501A1 (en) * 2017-03-07 2018-09-13 Jmva Biotech Ab Modified adsorptive surfaces
EP3546476A1 (en) * 2018-03-26 2019-10-02 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
KR20200035112A (ko) 2017-08-07 2020-04-01 리플리겐 코포레이션 C-말단 나선형 영역에 시스테인을 갖는 fc 결합 단백질
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
EP3706804B1 (en) 2017-11-07 2022-02-23 Navigo Proteins GmbH Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
US11629168B2 (en) 2017-11-09 2023-04-18 Tosoh Corporation Immunoglobulin-binding protein
GB2569585A (en) 2017-12-20 2019-06-26 Ge Healthcare Bio Sciences Ab A method for preparation of a separation matrix
GB201800448D0 (en) * 2018-01-11 2018-02-28 Puridify Ltd Chromatography media and methods for producing them
EP4249097A3 (en) 2018-02-01 2024-01-10 Repligen Corporation Fc binding proteins with cysteine in the c-terminal helical region
AR115024A1 (es) 2018-03-28 2020-11-18 Bristol Myers Squibb Co PROTEÍNAS DE FUSIÓN INTERLEUCINA-2 / RECEPTOR a DE INTERLEUCINA-2 Y MÉTODOS DE USO
CN114903978A (zh) 2018-07-03 2022-08-16 百时美施贵宝公司 Fgf-21配制品
WO2020040307A1 (ja) * 2018-08-24 2020-02-27 Jsr株式会社 イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
KR20210122788A (ko) * 2019-02-01 2021-10-12 나피고 프로타인스 게엠베하 친화도 정제를 위한 면역글로불린 결합 단백질
GB201904125D0 (en) 2019-03-26 2019-05-08 Ge Healthcare Bio Sciences Ab Method for sanitization of a chromatography column
JP7432813B2 (ja) 2019-09-10 2024-02-19 東ソー株式会社 免疫グロブリン結合性タンパク質
JP2022551837A (ja) * 2019-10-08 2022-12-14 ノース カロライナ ステート ユニバーシティ 免疫グロブリン精製ペプチド、及びその使用
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
EP4229068A1 (en) 2020-10-13 2023-08-23 Avitide LLC Affinity ligand libraries of three-helix bundle proteins and uses thereof
WO2022178396A1 (en) 2021-02-19 2022-08-25 Avitide LLC Aav2 affinity agents
GB202113626D0 (en) 2021-09-24 2021-11-10 Cytiva Bioprocess R & D Ab FC binding polypeptides
GB202203478D0 (en) 2022-03-14 2022-04-27 Cytiva Bioprocess R & D Ab Vh3 binding polypeptides
CN117700501A (zh) * 2022-09-13 2024-03-15 普米斯生物技术(珠海)有限公司 免疫球蛋白结合蛋白及其应用

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE451946B (sv) 1982-12-10 1987-11-09 Gambro Lundia Ab Anordning for avlegsnande av en eller flera fraktioner ur helblod, plasma eller liknande kroppsvetskor
US4704366A (en) 1984-06-22 1987-11-03 Bio-Rad Laboratories, Inc. Process for binding IgG to protein A
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5011686A (en) 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5084398A (en) 1987-11-20 1992-01-28 Creative Biomolecules Selective removal of immune complexes
US4933435A (en) 1989-04-05 1990-06-12 Bioprobe International Antibody purification process
WO1993002107A1 (en) * 1991-07-25 1993-02-04 Oriental Yeast Co., Ltd. Immunoglobulin-combining artificial protein
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
SE9503925D0 (sv) 1995-11-07 1995-11-07 Pharmacia Biotech Ab Separationsmedium för IgG
SE9601368D0 (sv) 1996-04-11 1996-04-11 Pharmacia Biotech Ab Process for the production of a porous cross-linked polysaccharide gel
IL130061A (en) 1996-11-27 2001-09-13 Genentech Inc Affinity purification of polypeptide on protein a matrix
ATE417858T1 (de) 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
US7709209B2 (en) 2002-03-25 2010-05-04 Ge Healthcare Bio-Sciences Ab Protein ligands
SE0200943D0 (sv) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
NZ539297A (en) 2002-09-13 2008-04-30 Biogen Idec Inc Method of purifying polypeptides by simulated moving bed chromatography
US20050097625A1 (en) 2002-11-27 2005-05-05 Meade Harry M. Modified antibodies stably produced in milk and methods of producing same
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
SE0402322D0 (sv) 2004-09-22 2004-09-22 Amersham Biosciences Ab Method of preparing a chromatography matrix
JP2006304633A (ja) 2005-04-26 2006-11-09 Apro Life Science Institute Inc イムノグロブリン結合タンパク質
CN104926938B (zh) 2005-06-17 2019-06-04 惠氏有限责任公司 纯化含Fc区蛋白的方法
WO2007021807A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
AU2007204987B2 (en) 2006-01-06 2011-11-24 Amgen Inc. Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
AU2007205935B2 (en) 2006-01-17 2013-07-11 Synthon Biopharmaceuticals B.V. Compositions and methods for humanization and optimization of N-glycans in plants
WO2007097361A1 (ja) 2006-02-21 2007-08-30 Protenova Co., Ltd. イムノグロブリン親和性リガンド
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
LT2004683T (lt) 2006-03-24 2016-10-10 Biogen Hemophilia Inc. Pc5, kaip faktoriaus ix pro-peptidą apdorojantis fermentas
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2007144476A1 (fr) 2006-06-16 2007-12-21 Groupe Novasep Procede de separation sequence multicolonnes
ATE480568T1 (de) 2006-06-30 2010-09-15 Conaris Res Inst Ag Verbesserte sgp 130fc dimere
EP2061802A1 (en) 2006-08-28 2009-05-27 Ares Trading S.A. Process for the purification of fc-fusion proteins
TW200821026A (en) 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
CN101522278B (zh) 2006-09-29 2016-08-10 通用电气健康护理生物科学股份公司 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体
JP5448825B2 (ja) 2006-10-19 2014-03-19 ヤンセン バイオテツク，インコーポレーテツド 非凝集抗体Ｆｃドメインの製造方法
WO2008127457A2 (en) * 2006-12-06 2008-10-23 Repligen Corporation Nucleic acids encoding recombinant protein a
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
JP5522723B2 (ja) * 2007-05-21 2014-06-18 ノマディックバイオサイエンス株式会社 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法
US7901581B2 (en) 2007-06-15 2011-03-08 Ge Healthcare Bio-Sciences Ab Chromatography method
CA2722348A1 (en) 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
US20110144311A1 (en) 2008-08-14 2011-06-16 Rebecca Chmielowski Methods for purifying antibodies using protein a affinity chromatography
JP5229888B2 (ja) 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
JPWO2010110288A1 (ja) 2009-03-24 2012-09-27 株式会社カネカ 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド
US8728479B2 (en) 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
KR20110139292A (ko) 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
EP3702775A1 (en) 2009-06-26 2020-09-02 Cytiva Sweden AB Method for determining binding capacities in a chromatography system
CN102471378B (zh) 2009-06-26 2014-04-02 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
EP2470561A1 (en) 2009-08-27 2012-07-04 Novo Nordisk A/S Targeting tissue factor to activated platelets
SI2483310T1 (sl) 2009-09-29 2014-12-31 Roche Glycart Ag Bispecifiäśna agonistiäśna protitelesa receptorja smrti
WO2011073389A1 (en) 2009-12-18 2011-06-23 Novartis Ag Wash solution and method for affinity chromatography
CN102712673B (zh) 2010-01-22 2014-04-30 贝林格尔.英格海姆国际有限公司 用于纯化含fc的蛋白的色谱方法
JP5917417B2 (ja) 2010-03-05 2016-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体の選択的強化
US10273270B2 (en) 2010-03-24 2019-04-30 Kaneka Corporation Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
FR2958936A1 (fr) 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
TWI586806B (zh) 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
KR101152036B1 (ko) 2010-04-27 2012-06-08 (주)셀트리온 컬럼 순환 및 시료 연속주입법을 이용한 단백질 ａ 크로마토그래피 정제 방법
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
BR112012031329A2 (pt) 2010-06-09 2016-10-11 Zymogenetics Inc proteínas de fusão diméricas vstm3 e composições e métodos relacionados
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2012068317A2 (en) 2010-11-16 2012-05-24 Excelimmune, Inc. Methods for producing recombinant proteins
WO2012074463A1 (en) 2010-11-29 2012-06-07 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
JP5974343B2 (ja) 2010-12-20 2016-08-23 ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ アフィニティークロマトグラフィーマトリックス
CN103269761B (zh) * 2010-12-20 2016-05-18 通用电气健康护理生物科学股份公司 亲和色谱基质
JP5997176B2 (ja) 2010-12-21 2016-09-28 ザ ユニバーシティ オブ ウエスタン オンタリオＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｗｅｓｔｅｒｎ Ｏｎｔａｒｉｏ プロテインａの新規アルカリ抵抗性変異体及びアフィニティークロマトグラフィーにおけるその使用
CN103270044B (zh) 2010-12-21 2016-03-09 Jsr株式会社 亲和色谱用载体和分离免疫球蛋白的方法
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2012125735A1 (en) 2011-03-15 2012-09-20 Abott Laboratories An integrated approach to the isolation and purification of antibodies
US10065995B2 (en) * 2011-03-25 2018-09-04 Kaneka Corporation Protein for affinity-separation matrix
JP5933526B2 (ja) 2011-03-25 2016-06-08 株式会社カネカ 免疫グロブリン結合性新規ポリペプチド
SG193545A1 (en) 2011-03-29 2013-11-29 Glaxosmithkline Llc Buffer system for protein purification
CN102757930A (zh) * 2011-04-27 2012-10-31 长春安贝生物科技有限公司 超低IgG新生牛血清生产工艺
CA2834300C (en) 2011-06-01 2022-01-11 Novartis Ag Wash solution and method for affinity chromatography
EP2728000B1 (en) 2011-06-03 2018-12-05 National Institute of Advanced Industrial Science And Technology Protein a mutant protein having reduced affinity in acidic region, and antibody capture agent
WO2013006244A1 (en) 2011-06-08 2013-01-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific monoclonal antibody therapeutics against west nile virus with improved cns penetration
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
CN103649125A (zh) 2011-06-22 2014-03-19 霍夫曼-拉罗奇有限公司 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
BR112014000055A2 (pt) 2011-07-01 2017-06-13 Bayer Ip Gmbh polipeptídeos de fusão de relaxina e usos dos mesmos
WO2013009526A1 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
BR112014000474A2 (pt) 2011-07-08 2017-02-21 Bayer Ip Gmbh proteínas de fusão libertadoras de relaxina e suas utilizações
CA2847173A1 (en) 2011-09-01 2013-03-07 Human Genome Sciences, Inc. Viral clearance methods
CA2845147A1 (en) 2011-09-23 2013-03-28 Roche Glycart Ag Bispecific anti-egfr/anti igf-1r antibodies
CN108152513B (zh) 2011-09-29 2020-07-24 西雅图基因公司 蛋白偶联的试剂化合物的整体分子量测定
EP2578286A1 (en) 2011-10-04 2013-04-10 Merck Patent GmbH Method and apparatus for chromatographic purification
AU2012328322A1 (en) 2011-10-27 2014-06-12 Genmab A/S Production of heterodimeric proteins
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
US9657055B2 (en) 2011-11-30 2017-05-23 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
US9446123B2 (en) 2012-06-01 2016-09-20 Ibc Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
KR20150031217A (ko) 2011-12-15 2015-03-23 더 로얄 인스티튜션 포 디 어드밴스먼트 오브 러닝/맥길 유니버시티 가용성 igf 수용체 fc 융합 단백질 및 이의 용도
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
US10189891B2 (en) 2012-03-28 2019-01-29 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
AU2013244999A1 (en) 2012-04-05 2014-09-25 F. Hoffmann-La Roche Ag Bispecific antibodies against human TWEAK and human IL17 and uses thereof
EP2656892A1 (en) 2012-04-23 2013-10-30 Merck Patent GmbH Chromatography method
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
EP2880057A4 (en) 2012-08-02 2016-03-23 Jn Biosciences Llc MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
ES2633894T3 (es) 2012-08-02 2017-09-25 F. Hoffmann-La Roche Ag Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas
EP2880170B1 (en) 2012-08-02 2016-08-24 F. Hoffmann-La Roche AG METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
ES2879387T3 (es) 2012-09-13 2021-11-22 Bristol Myers Squibb Co Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina
US9920098B2 (en) * 2012-09-21 2018-03-20 Kaneka Corporation Protein ligand for affinity isolation matrix
ES2819573T3 (es) 2012-12-13 2021-04-16 Immunomedics Inc Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
JP2016509014A (ja) 2013-02-08 2016-03-24 ステムセントリックス， インコーポレイテッド 新規の多特異的構成物
DK2772289T3 (en) 2013-03-01 2015-08-10 Chromacon Ag Chromatographic method for the enrichment and isolation
JP6285532B2 (ja) 2013-03-14 2018-02-28 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質ａに基づくクロマトグラフィを使用するタンパク質純度を増加させる方法
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN104059133B (zh) 2013-03-18 2019-03-15 南京金斯瑞生物科技有限公司 一类突变的具有高耐碱特性的蛋白a及其应用
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
CA2910065C (en) 2013-05-15 2023-09-19 Medimmune Limited Purification of recombinantly produced polypeptides
WO2014192877A1 (ja) 2013-05-29 2014-12-04 Jsr株式会社 洗浄用組成物、タンパク質精製方法、及びタンパク質
JP2016531088A (ja) 2013-06-17 2016-10-06 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー ５ｔ４標的化免疫融合分子および方法
PL3020731T3 (pl) 2013-07-09 2019-11-29 Ablbio Nowe podwójnie nakierowane białko specyficznie wiążące się z dll4 i vegf oraz zastosowanie tego białka
EP3019520B1 (en) 2013-07-10 2019-12-11 GE Healthcare BioProcess R&D AB Mutated immunoglobulin-binding polypeptides
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
SG11201600171SA (en) 2013-08-02 2016-02-26 Pfizer Anti-cxcr4 antibodies and antibody-drug conjugates
CA2922832A1 (en) 2013-09-05 2015-03-12 Genentech, Inc. Method for chromatography reuse
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
CA2921707C (en) 2013-10-15 2023-03-28 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
KR102178323B1 (ko) 2013-11-29 2020-11-13 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
PL3082877T3 (pl) 2013-12-17 2020-02-28 Novartis Ag Cytotoksyczne peptydy i ich koniugaty
CN106459055B (zh) 2014-01-27 2019-11-01 辉瑞大药厂 双功能细胞毒类药剂
WO2015130766A1 (en) 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
US10323095B2 (en) 2014-03-17 2019-06-18 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
CN106456714A (zh) 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
CN106456798B (zh) 2014-04-25 2021-02-12 瑞纳神经科学公司 具有高药物负载的抗体-药物缀合物
EP4147761A1 (en) 2014-04-30 2023-03-15 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
MX2016014862A (es) 2014-05-14 2017-02-27 Hoffmann La Roche Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
AU2015265457B2 (en) 2014-05-28 2021-02-18 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
BR112016029157A8 (pt) 2014-06-13 2021-07-06 Lupin Ltd processo para purificar a proteína de fusão tnfr:fc
MX2016016515A (es) 2014-06-13 2017-04-27 Novartis Ag Derivados de auristatina y conjugados de los mismos.
US9777073B2 (en) 2014-07-21 2017-10-03 Wuhan Yzy Biopharma Co., Ltd. Construction and application of bispecific antibody EpCAM×CD3
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
KR102259232B1 (ko) 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
WO2016030791A1 (en) 2014-08-28 2016-03-03 Pfizer Inc. Stability-modulating linkers for use with antibody drug conjugates
JP6783754B2 (ja) 2014-09-17 2020-11-11 ノヴォ ノルディスク アー／エス 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
EP3093034B1 (en) * 2014-10-24 2019-12-18 Gemtier Medical (Shanghai) Inc. Disposable anti-acupuncture intravenous infusion puncture needle
US11566082B2 (en) * 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107249643A (zh) 2014-12-09 2017-10-13 艾伯维公司 具有细胞渗透性的bcl‑xl抑制剂的抗体药物缀合物
CN111620862A (zh) 2014-12-09 2020-09-04 艾伯维公司 Bcl-xl抑制性化合物和包括其的抗体药物缀合物
US10865253B2 (en) 2014-12-19 2020-12-15 Genmab A/S Rodent bispecific heterodimeric proteins
CA2975410A1 (en) 2015-04-07 2016-10-13 Immunomedics, Inc. Y-90-labeled anti-cd22 antibody (epratuzumab tetraxetan) in refractory/relapsed adult cd22+ b-cell acute lymphoblastic leukemia
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
US20180194861A1 (en) 2015-07-10 2018-07-12 Abbvie Inc. IgM- or IgE-Modified Binding Proteins and Uses Thereof
GB201515339D0 (en) 2015-08-28 2015-10-14 Ge Healthcare Bio Sciences Ab A seperation matrix and a method of seperating antibodies
EP3353201B1 (en) 2015-09-25 2021-09-08 F. Hoffmann-La Roche AG Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
CN108026179A (zh) 2015-10-02 2018-05-11 豪夫迈·罗氏有限公司 结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
EP3356403A2 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
MX2018004157A (es) 2015-10-07 2019-04-01 F Hoffmann ­La Roche Ag Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
TWI637966B (zh) 2015-11-30 2018-10-11 輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix

Also Published As

Publication number Publication date
JP2020184999A (ja) 2020-11-19
KR20170085502A (ko) 2017-07-24
US20170334954A1 (en) 2017-11-23
JP2017536819A (ja) 2017-12-14
JP2020178696A (ja) 2020-11-05
SG11201703053PA (en) 2017-05-30
WO2016079033A1 (en) 2016-05-26
RU2017115342A3 (sl) 2019-04-05
RU2712882C2 (ru) 2020-01-31
KR20170078693A (ko) 2017-07-07
CN107001432A (zh) 2017-08-01
CN107001432B (zh) 2022-02-18
SG11201702796WA (en) 2017-05-30
KR102552335B1 (ko) 2023-07-07
EP3221347A1 (en) 2017-09-27
JP6770727B2 (ja) 2020-10-21
RU2017115345A3 (sl) 2019-04-02
ES2817900T3 (es) 2021-04-08
JP2017533924A (ja) 2017-11-16
EP3221338B1 (en) 2020-10-28
JP2022062096A (ja) 2022-04-19
AU2015348641A1 (en) 2017-04-27
JP7015868B2 (ja) 2022-02-03
US20200079878A1 (en) 2020-03-12
AU2015348640B2 (en) 2021-07-15
JP6724000B2 (ja) 2020-07-15
WO2016079034A1 (en) 2016-05-26
EP3757123A1 (en) 2020-12-30
AU2015348641B2 (en) 2020-06-25
US20210147577A1 (en) 2021-05-20
RU2017115345A (ru) 2018-12-19
RU2701695C2 (ru) 2019-09-30
US11566082B2 (en) 2023-01-31
EP3221347B1 (en) 2020-08-19
DK3221347T3 (da) 2020-09-21
AU2015348640A1 (en) 2017-04-27
US20230331870A1 (en) 2023-10-19
EP3221338A1 (en) 2017-09-27
US20180327512A1 (en) 2018-11-15
DE112015005181T5 (de) 2017-08-24
RU2017115342A (ru) 2018-12-19
US10501557B2 (en) 2019-12-10
BR112017008106A2 (pt) 2018-03-06
EP3757124A1 (en) 2020-12-30
CN107001448A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
SG11201703053PA (en) Mutated immunoglobulin-binding polypeptides
ZA201802261B (en) Polypeptides
IL255767A (en) New polypeptides
HK1250041A1 (zh) 多肽
HK1245832A1 (zh) 嵌合多肽
ZA201704366B (en) Il-17a-binding polypeptides
HK1250040A1 (zh) 多肽
PL3240684T3 (pl) Materiał budowlany
ZA201701348B (en) New polypeptides
GB201412756D0 (en) Construction material
SI3087179T1 (sl) Fuzijski polipeptidi z izboljšanimi lastnostmi, povezani z omega hidroksilazo
PL2902575T3 (pl) System okuciowy
ZA201701071B (en) Modified vip3 polypeptides
IL246533A0 (en) new proteins
PL3031357T3 (pl) Okucie wychylne
GB201608229D0 (en) Mutated immunoglobulin-binding polypeptides
GB201510261D0 (en) Mutated immunoglobulin-binding polypeptides
GB201510263D0 (en) Mutated immunoglobulin-binding polypeptides
GB201419237D0 (en) Novel polypeptides
GB201403024D0 (en) Polypeptides
GB201410265D0 (en) Novel polypeptides
GB201515245D0 (en) Novel polypeptides
PL2899341T3 (pl) System okuciowy
GB201403309D0 (en) Detecting polypeptides
GB201400508D0 (en) Mutant polypeptides